

PTO/SB/01A (10-00).
Approved sorryse streetign 10/31/2002. OMB 0651-0032. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	COMPOSITIONS AND METHODS DIAGNOSIS OF BREAST CANCE		THERAPY AND
This declaration is direct	ventor(s), I/we declare that: cted to: ed application, or		
<u>–</u>	ed application, or No. <u>10/076,622</u> , filed on <u>February 13, .</u>	2002	
:	nded on (if applicable);	<u> 2002,</u>	
_	m/are the original and first inventor(s)	of the subject	matter which is claimed and for
	I understand the contents of the abovedment specifically referred to above;	-identified app	lication, including the claims, as
known to me/us to be which became available	duty to disclose to the United States material to patentability as defined in be between the filing date of the prior apparation-in-part application, if applicable;	37 CFR 1.56 plication and tl	s, including material information
and belief are believed willful false statements	erein of my/our own knowledge are tru to be true, and further that these sta and the like are punishable by fine or i validity of the application or any patent	itements were imprisonment,	made with the knowledge that or both, under 18 U.S.C. 1001,
FULL NAME OF INVEN	TOR(S)		The second of th
Inventor one: Raym	nond L. Houghton	Citizen of:	US
Signature:	and he Hought	Date:	3/29/02
Inventor two: Paul I	R. Sleath	Citizen of:	US
Signature: Lau	I Robbin	Date:	3/29/02
Inventor three: David	H. Persing	Citizen of:	US
Signature:	wh	Date:	4-5-02
Inventor four:		Citizen of:	
Signature:		Date:	
☐ Additional inventors	s are being named on additional form	(s) attached her	reto

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231. Docket No. 210121.470C11 265544

+

PTO/SB/81 (10-00)

Approved for use through 10/31/2002. OMB 0651-0035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ELECTION AND POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

10/076,622 Application Numb r February 13, 2002 Filing Date Raymond L. Houghton First Named Inventor Group Art Unit **Examiner Name** 210121.470C11 Attorney Docket Number

I hereby appoin Practitioners OR Practitioner(s)	at Seed IP Law Group PLLC		00500 PATENT TRADEMARK OF	FICE	
	Name	Registration	Number		
<u></u>					
	ey(s) or agent(s) to prosecute the application id e connected therewith.	entified above, and to tr	ansact all business in	the Patent and	
m	ne correspondence address for the above-ident ntioned Customer Number.	ified application to:			
Firm <i>or</i> Individual Na	me				
Address					
Address					
City	S	tate	ZIP		
Country					
Telephone		Fax			
I am the: Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). As assignee of record of the entire interest I/we hereby elect, under 37 C.F.R. § 3.71, to prosecute the application to the exclusion of the inventor.					
	SIGNATURE of Applicant	or Assignee of Recor	d		
Name Kathleen Nora McKereghan					
Signature	Signature (a.Cleh my my)				
Date 2 May 2002 ()					
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.					
*Total of					

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



EREAS, we,

Name Post Office Address

Raymond L. Houghton 2636 242nd Place Southeast, Bothell, WA 98021 ;

Paul R. Sleath 1623 Eighth Avenue West, Seattle, WA 98119 ; and

David H. Persing 22401 Northeast 25th Way, Redmond, WA 98053 ,

(hereinafter referred to as ASSIGNORS), having post office addresses as listed above next to our names, are the joint inventors of an invention entitled

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER

which is described and claimed in the specification and claims of continuation-in-part (C-I-P) Patent Application No. 10/076,622, as filed in the United States Patent and Trademark Office on February 13, 2002 ("this application") for which a patent is sought. This application derives benefit from the following application(s):

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number	Attorney Docket Number
10/007,805	12/07/01		210121.470C10
09/834,759	04/13/01		210121.470C9
09/620,405	07/20/00		210121.470C8
09/604,287	06/22/00		210121.470C7
09/590,751	06/08/00		210121.470C6
09/551,621	04/17/00		210121.470C5
09/433,826	11/03/99		210121.470C4
09/389,681	09/02/99		210121.470C3
09/339,338	06/23/99		210121.470C2
09/285,480	04/02/99		210121.470C1

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number	Attorney Docket Number	
09/222,575	12/28/98		210121.470	

WHEREAS, Corixa Corporation (hereinafter referred to as ASSIGNEE), a corporation of the State of Delaware having a place of business at 1124 Columbia Street, Suite 200, Seattle, Washington 98104, is desirous of acquiring the entire right, title and interest in and to said invention, this application, and in and to any Letters Patent that may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNORS hereby sell, assign and transfer unto said ASSIGNEE, the entire right, title and interest in and to said invention, this application and any and all Letters Patent which may be granted therefor in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from this application and said parent application(s) to which said foreign applications are entitled by virtue of international convention, treaty or otherwise; said invention, this application and all Letters Patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNORS had this assignment, transfer and sale not been made.

ASSIGNORS hereby authorize and request the Director of the Patent and Trademark Office to issue said United States Patent to ASSIGNEE, of the entire right, title and interest in and to the same, for its sole use and benefit, and for the use and behalf of its legal representatives, to the full end of the term for which said Patent may be granted, as fully and entirely as the same would have been held by us had this assignment and sale not been made.

ASSIGNORS agree to execute all instruments and documents required for the making and prosecution of applications for United States and foreign Patent on said invention,

Patent therei	or.
•	3/29/02 Raynord a Hought
Date	Raymond DHoughton
State of	WASHINGTON
<u></u>	KING) ss.
County of _	
instrument a	I certify that I know or have satisfactory evidence that Raymond L. Houghton is who appeared before me, and said person acknowledged that he signed this and acknowledged it to be his free and voluntary act for the uses and purposes a the instrument. Dated Signature of Notary Public Printed Name DEIRDRE I. BRYAN
	My appointment expires $\frac{9/1}{0}$
	wiy appointment expires
Date 2	Paul R. Sleath
State of	hacil NGTON) ss.
County of _	KING
	I certify that I know or have satisfactory evidence that Paul R. Sleath is the person ed before me, and said person acknowledged that he signed this instrument and ed it to be his free and voluntary act for the uses and purposes mentioned in the
	Dated
	Signature of Notary Public Mende I Bryan
	Printed Name DEIRDRE I. BRYAN
	My appointment expires 9/1/02

for litigation regarding said Patent, or for the purpose of protecting title to said invention or

	1/5/02		David of
Date	/		David H. Persing
State of	WASHINGTON)	
County of	KING)	SS.

I certify that I know or have satisfactory evidence that David H. Persing is the person who appeared before me, and said person acknowledged that he signed this instrument and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated	epul 5, 2002	
Signature of Notary Public	Wendre I Bryan	
Printed Name	DEIRDRE I. BRYAN	
My appointmen	at expires $9/i/oz$	

265583



results of BLAST

BLASTP 2.2.6 [Apr-09-2003]

Reference:

Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schäffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

RID: 1061299431-06061-3105

Query=

(50 letters)

Database: All non-redundant GenBank CDS

translations+PDB+SwissProt+PIR+PRF

1,503,231 sequences; 484,217,701 total letters


4,17,2000

If you have any problems or questions with the results of this search please refer to the ${\tt BLAST}$ FAQs

Taxonomy reports

4,1999

Distribution of 4 Blast Hits on the Query Sequence



Sequences producing significant alignments:

Score E (bits) Value

gi	16506285 ref NP_443723.1	breast cancer antigen NY-BR-1	94	7e-19 📙
gi	13469731 gb AAK27326.1	breast cancer antigen NY-BR-1.1	65	4e-10
gi	21758774 dbj BAC05379.1	unnamed protein product [Homo s	_56	2e-07 👢
gi	15678010 ref NP_274455.1	DNA polymerase III, subunits g	31	6.1

Alignments

Get selected sequences | Select all | Deselect all

```
Score = 93.6 bits (231), Expect = 7e-19
 Identities = 50/50 (100%), Positives = 50/50 (100%)
           MSPAKETSEKFTWAAKGRPRKIAWEKKETPVKTGCVARVTSNKTKVLEKG 50
Query: 1
           MSPAKETSEKFTWAAKGRPRKIAWEKKETPVKTGCVARVTSNKTKVLEKG
Sbjct: 340 MSPAKETSEKFTWAAKGRPRKIAWEKKETPVKTGCVARVTSNKTKVLEKG 389
____>gi|13469731|gb|AAK27326.1|
                               breast cancer antigen NY-BR-1.1 [Homo sapiens]
          Length = 1011
 Score = 64.7 bits (156), Expect = 4e-10
 Identities = 36/50 (72%), Positives = 40/50 (80%)
           MSPAKETSEKFTWAAKGRPRKIAWEKKETPVKTGCVARVTSNKTKVLEKG 50
           + P KETSEKF+W AK R RKI WE+KET VKT CVA VT NKT+VLEKG
Sbjct: 187 LRPTKETSEKFSWPAKERSRKITWEEKETSVKTECVAGVTPNKTEVLEKG 236
sqi|21758774|dbj|BAC05379.1| unnamed protein product [Homo sapiens]
          Length = 168
 Score = 55.8 bits (133), Expect = 2e-07
 Identities = 37/50 (74%), Positives = 39/50 (78%)
Query: 1 MSPAKETSEKFTWAAKGRPRKIAWEKKETPVKTGCVARVTSNKTKVLEKG 50
          M AKETSEKF W AK RPRKI WE+KET VKT CVA V NKT+VLEKG
Sbjct: 47 MRTAKETSEKFAWPAKERPRKITWEEKETSVKTECVAGVIPNKTEVLEKG 96
| >gi | 15678010 | ref | NP 274455.1 | DNA polymerase III, subunits gamma and tau, progra
           [Neisseria meningitidis MC58]
          Length = 704
 Score = 30.8 bits (68), Expect = 6.1
 Identities = 18/40 (45%), Positives = 25/40 (62%), Gaps = 1/40 (2%)
Query: 2
           SPAKETSEKFTWAAKGRPRKIAWEKKETPVKTGCVARVTS 41
           SP+ +T+EK T A K +PR A E +TPV+T
Sbjct: 379 SPSAQTAEKETAAKKPQPRPEA-ETAQTPVQTASAAAMPS 417
     Get selected sequences
                             Select all
                                        Deselect all
  Database: All non-redundant GenBank CDS
  translations+PDB+SwissProt+PIR+PRF
    Posted date: Aug 18, 2003 4:29 AM
  Number of letters in database: 484,217,701
  Number of sequences in database: 1,503,231
Lambda
   0.308
           0.122
Gapped
Lambda
           K
   0.267
           0.0410
Matrix: BLOSUM62
Gap Penalties: Existence: 11, Extension: 1
Number of Hits to DB: 46,762,076
Number of Sequences: 1503231
Number of extensions: 1192855
Number of successful extensions: 1740
Number of sequences better than 10.0: 4
Number of HSP's better than 10.0 without gapping: 3
```

```
Number of HSP's successfully gapped in prelim test: 1
Number of HSP's that attempted gapping in prelim test: 1725
Number of HSP's gapped (non-prelim): 15
length of query: 50
length of database: 484,217,701
effective HSP length: 26
effective length of query: 24
effective length of database: 445,133,695
effective search space: 10683208680
effective search space used: 10683208680
T: 11
A: 40
X1: 16 ( 7.1 bits)
X2: 38 (14.6 bits)
X3: 64 (24.7 bits)
S1: 42 (21.7 bits)
S2: 66 (30.0 bits)
```





Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction App of 1895 no persons are required to respond to a collection of information unless it displays a valid OMB control number. STATEMENT UNDER 37 CFR 3.73(b) Applicant/Patent Owner: ____ Raym nd L. H ughton et al. Application No./Patent No.: 10/076,622 Filed/Issue Date: February 13, 2002 Entitled: COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF **BREAST CANCER** Corixa Corporation corporation (Type of Assignee, e.g., corporation, partnership, (Name of Assignee) university, government agency, etc.) states that it is: 1. X the assignee of the entire right, title, and interest; or 2. | an assignee of an undivided part interest in the patent application/patent identified above by virtue of either: A. X An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached. OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below: 1. From: To: The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached 2. From: To: The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached From:_ To: The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. Kathleen Nora McKereghan Typed or printed name Senior Vice President, General Counsel and Secretary

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.